692 results on '"Gladman, Dafna D"'
Search Results
2. BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies
3. Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus
4. Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study
5. Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis
6. Residual Disease Activity In Canadian Patients With Psoriatic Arthritis (PsA) Treated With Advanced Therapies: Results From A Multi-Registry Analysis (UNISON-PsA)
7. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
8. Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment
9. Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis
10. Circulating neutrophil extracellular trap remnants as a biomarker to predict outcomes in lupus nephritis
11. Different Immunologic Profiles Are Associated With Distinct Clinical Phenotypes in Longitudinally Observed Patients With Systemic Lupus Erythematosus
12. Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort
13. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
14. Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
15. Incidence and predictors of demyelinating disease in spondyloarthritis: data from a longitudinal cohort study
16. Increased Risk of Severe Generalized Pustular Psoriasis due to Tuberculosis Screening Delay for Spesolimab Initiation
17. Metrics in Disease Activity Measures in Systemic Lupus Erythematosus
18. Psoriatic Arthritis and COVID-19: Patient Perspectives in a Large Psoriatic Arthritis Cohort
19. Derivation of a multivariable psoriatic arthritis risk estimation tool (PRESTO): a step towards prevention
20. Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting
21. Proceedings of the GRAPPA 2022 Executive Retreat
22. PREDICTION OF PSORIATIC ARTHRITIS IN PATIENTS WITH PSORIASIS USING DNA METHYLATION PROFILES
23. Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 Annual Meeting
24. Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group
25. Project Highlights From the GRAPPA 2022 Annual Meeting: Education Initiatives and Axial Involvement in Psoriatic Arthritis
26. LO-024 Association between severe non-adherence to hydroxychloroquine and SLE flares, damage, and mortality in 660 patients from the SLICC inception cohort
27. Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestations
28. Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic Challenge (SWITCH): The Systemic Lupus International Collaborating Clinics experience
29. Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
30. Correspondence on “relationship between the EULAR/ACR classification criteria and organ damage in systemic lupus erythematosus” by Chi Chiu Mok et al
31. Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes
32. Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
33. Persistence of Biologics in the Treatment of Psoriatic Arthritis (Psa): Data From a Large Hospital Based Longitudinal Cohort
34. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension
35. Cardiac Magnetic Resonance Imaging T1 and T2 Mapping in Systemic Lupus Erythematosus in Relation to Antimalarial Treatment
36. Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics (SLICC) Cohort using Multistate Modelling
37. Genetics of osteonecrosis in children and adults with systemic lupus erythematosus
38. Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network
39. Cardiac Magnetic Resonance Imaging and Clinical Follow-up in Antimalarial-induced Cardiomyopathy in Patients With Systemic Lupus Erythematosus
40. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
41. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
42. Evaluating the Construct of Damage in Systemic Lupus Erythematosus
43. Real-World Retention and Clinical Effectiveness of Secukinumab for Psoriatic Arthritis: Results From the Canadian Spondyloarthritis Research Network
44. Improving measures of disease activity in systemic lupus erythematosus
45. 1117 Neutrophil extracellular traps as a biomarker to predict outcomes in lupus nephritis
46. 102 M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort
47. The new EULAR/ACR 2019 SLE classification criteria: A predictor of long-term outcomes
48. 603 Remission and low disease activity are associated with lower health care costs in an international inception cohort of patients with systemic lupus erythematosus
49. Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors
50. Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.